Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06875986). This is a study registration, not published results. Lead sponsor: Otsuka Pharmaceutical Co., Ltd.. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Alzheimer Disease. Interventions: DRUG: Brexpiprazole (Rexulti). Primary outcome measures: Safety Information (Adverse Event) , 24 weeks from the initiation of brexpiprazole treatment; Safety Information (Special Situations) , 24 weeks from the initiation of brexpiprazole treatment; Safety Information (Number of off-Label Use) , 24 weeks from the initiation of brexpiprazole treatment; Safety Information (Serious Adverse Event) , 24 weeks from the initiation of brexpiprazole treatment; Safety Information (Non-serious Adverse Events) , 24 weeks from the initiation of brexpiprazole treatment. Brief summary: The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.